DRUG REGISTRATION GUIDANCE DOCUMENT (DRGD) - BPFK

More documents

Recommendations

Info

Drug Registration Guidance Document (DRGD)Table 3: Details of Specific Labelling RequirementsNO.SPECIFIC LABELLING REQUIREMENTS (SUBSTANCE SPECIFIC)1. 5-ALPHA REDUCTASE INHIBITOR (5-ARI)The following statement shall be included in the package inserts of productscontaining 5-ARI:1.1 PRODUCT CONTAINING FINASTERIDE 5MGWARNINGS AND PRECAUTIONSIncreased Risk of High-Grade Prostate CancerMen aged 55 and over with a normal digital rectal examination and PSA≤3.0 ng/mL at baseline taking finasteride 5 mg/day in the 7-year ProstateCancer Prevention Trial (PCPT) had an increased risk of Gleason score 8-10 prostate cancer (finasteride 1.8% vs placebo 1.1%). Similar resultswere observed in a 4-year placebo-controlled clinical trial with another 5-alpha reductase inhibitor (dutasteride, AVODART) (1% dutasteride vs0.5% placebo).5-alpha reductase inhibitors may increase the risk of development of highgradeprostate cancer. Whether the effect of 5-alpha reductase inhibitorsto reduce prostate volume, or study-related factors, impacted the results ofthese studies has not been established.Increased Risk of Breast CancerBreast cancer has been reported in men taking finasteride 5 mg during thepost-marketing period. Physicians should instruct their patients to promptlyreport any changes in their breast tissue such as lumps, pain,gynaecomastia or nipple discharge.ADVERSE EVENTS: POST MARKETING EXPERIENCEMale breast cancer1.2 PRODUCT CONTAINING FINASTERIDE 1MGWARNINGS AND PRECAUTIONSIncreased Risk of High-Grade Prostate CancerMen aged 55 and over with a normal digital rectal examination and PSA≤3.0 ng/mL at baseline taking finasteride 5 mg/day (5 times the dose of[Brand Name]) in the 7-year Prostate Cancer Prevention Trial (PCPT) hadan increased risk of Gleason score 8-10 prostate cancer (finasteride 1.8%vs placebo 1.1%). Similar results were observed in a 4-year placebocontrolledclinical trial with another 5-alpha reductase inhibitorNational Pharmaceutical Control Bureau (NPCB)First Edition, January 2013 Page | 356
Drug Registration Guidance Document (DRGD)NO.SPECIFIC LABELLING REQUIREMENTS (SUBSTANCE SPECIFIC)(dutasteride, AVODART) (1% dutasteride vs 0.5% placebo).5-alpha reductase inhibitors may increase the risk of development of highgradeprostate cancer. Whether the effect of 5-alpha reductase inhibitorsto reduce prostate volume, or study-related factors, impacted the results ofthese studies has not been established.Increased Risk of Breast CancerBreast cancer has been reported in men taking finasteride 1 mg during thepost-marketing period. Physicians should instruct their patients to promptlyreport any changes in their breast tissue such as lumps, pain,gynaecomastia or nipple discharge.ADVERSE EVENTS: POST MARKETING EXPERIENCEMale breast cancer1.3 PRODUCT CONTAINING DUTASTERIDEWARNINGS AND PRECAUTIONSIncreased Risk of High-Grade Prostate CancerIn men aged 50 to 75 years with a prior negative biopsy for prostatecancer and a baseline PSA between 2.5 ng/mL and 10.0 ng/mL takingAVODART in the 4-year Reduction by Dutasteride of Prostate CancerEvents (REDUCE) trial, there was an increased incidence of Gleasonscore 8-10 prostate cancer compared with men taking placebo(AVODART 1.0% versus placebo 0.5%). In a 7-year placebo-controlledclinical trial with another 5-alpha reductase inhibitor (finasteride 5 mg,PROSCAR), similar results for Gleason score 8-10 prostate cancer wereobserved (finasteride 1.8% versus placebo 1.1%).5-alpha reductase inhibitors may increase the risk of development of highgradeprostate cancer. Whether the effect of 5-alpha reductase inhibitorsto reduce prostate volume, or studyrelated factors, impacted the results ofthese studies has not been established.Reference:a) Circular Bil (19) dlm BPFK/PPP/01/03 Jld 1: Direktif untuk Memuatkan KenyataanAmaran Berkaitan dengan Risiko High-Grade Prostate Cancer dalam SisipBungkusan Semua Produk 5-Arib) Circular Bil (64) dlm BPFK/PPP/01/03 Jld 1: Direktif untuk Memuatkan KenyataanAmaran Berkaitan dengan Risiko Kanser Payudara Di Kalangan Pesakit Lelaki dalamSisip Bungkusan Semua Produk Yang Mengandungi FinasterideNational Pharmaceutical Control Bureau (NPCB)First Edition, January 2013 Page | 357
Page 1 and 2:
Drug Registration Guidance Document
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Appearance/organoleptic(odor, color
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
ATTACHMENT 1Drug Registration Guida
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
PART IV: CLINICAL DOCUMENTSDrug Reg
Page 230 and 231:
ATTACHMENT 2Drug Registration Guida
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
APPENDIX 5:Drug Registration Guidan
Page 238 and 239:
1. GENERAL INFORMATIONSDrug Registr
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Route of AdministrationTAMC(CFU/g o
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
e) Example of label approved by the
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307: Drug Registration Guidance Document
Page 406 and 407:
Page 408 and 409:
Page 410 and 411:
Page 412 and 413:
Page 414 and 415:
Page 416 and 417:
Page 418 and 419:
Page 420 and 421:
Page 422 and 423:
Page 424 and 425:
Page 426 and 427:
Page 428 and 429:
Page 430 and 431:
Page 432 and 433:
Page 434 and 435:
Page 436 and 437:
Page 438 and 439:
Page 440 and 441:
Page 442 and 443:
Page 444 and 445:
Page 446 and 447:
Page 448 and 449:
Page 450 and 451:
Page 452 and 453:
Page 454 and 455:
Page 456 and 457:
Page 458 and 459:
Page 460 and 461:
Page 462 and 463:
Page 464 and 465:
Page 466 and 467:
Page 468 and 469:
Page 470 and 471:
Page 472 and 473:
Page 474 and 475:
Page 476 and 477:
Page 478 and 479:
Page 480 and 481:
Page 482 and 483:
Page 484 and 485:
Page 486 and 487:
Page 488 and 489:
Page 490 and 491:
Page 492 and 493:
Page 494 and 495:
Page 496 and 497:
Page 498 and 499:
Page 500:
show all

DRUG REGISTRATION GUIDANCE DOCUMENT (DRGD) - BPFK

Create successful ePaper yourself

Delete template?

Save as template?